
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39251674
72086
10.1038/s41598-024-72086-8
Article
To prescribe or not: a two-center retrospective observational study of antibiotics usage and outcomes of COVID-19 in Turkey
http://orcid.org/0000-0002-4620-6755
Karakoc Hanife Nur hkarakocparlayan@ihv.umaryland.edu

12
http://orcid.org/0000-0002-1522-6083
Aydin Merve 3
http://orcid.org/0000-0003-3241-3259
Ozcan Safiye Nur 2
http://orcid.org/0000-0002-0860-0786
Olcar Yildiz 4
http://orcid.org/0000-0002-5004-5958
Sumlu Esra 5
http://orcid.org/0000-0001-6459-7182
Dindar Emine Kubra 6
http://orcid.org/0000-0003-1308-8569
Arslan Yusuf Kemal 7
http://orcid.org/0000-0001-7798-3605
Sajadi Mohammad M. 1
1 grid.411024.2 0000 0001 2175 4264 Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD USA
2 Department of Infectious Diseases and Clinical Microbiology, Bitlis Tatvan State Hospital, Bitlis, Turkey
3 https://ror.org/054341q84 grid.440457.6 0000 0004 0471 9645 Department of Medical Microbiology, Faculty of Medicine, KTO Karatay University, Konya, Turkey
4 Department of Infectious Diseases and Clinical Microbiology, Kastamonu State Hospital, Kastamonu, Turkey
5 https://ror.org/054341q84 grid.440457.6 0000 0004 0471 9645 Department of Medical Pharmacology, Faculty of Medicine, KTO Karatay University, Konya, Turkey
6 Department of Infectious Diseases and Clinical Microbiology, Bitlis State Hospital, Bitlis, Turkey
7 https://ror.org/05wxkj555 grid.98622.37 0000 0001 2271 3229 Department of Biostatistics, Faculty of Medicine, Çukurova University, Adana, Turkey
9 9 2024
9 9 2024
2024
14 210311 7 2024
3 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
This retrospective cohort study conducted in Turkey between December 2020 and June 2022 aimed to assess antibiotic use, bacterial co-infections, and the associated factors on mortality in hospitalized patients with mild-to-severe COVID-19. Among the 445 patients, 80% received antibiotics, with fluoroquinolones being the most common choice, followed by beta-lactams and combinations. Various clinical and laboratory parameters, including symptoms, comorbidities, CCI, oxygen requirements, and CRP levels were observed to be elevated in the antibiotic group. Non-survivors had more ICU admissions and longer hospital stays compared to survivors. We conducted a multivariate Cox regression analysis to evaluate factors related to mortality. However, we did not find an association between antibiotic use and mortality [HR 2.7 (95% CI 0.4–20)]. The study identified significant factors associated with an antibiotic prescription, such as CCI (OR 1.6), CRP (OR 2.3), and ICU admission (OR 8.8), (p < 0.05). The findings suggest re-evaluating the necessity of antibiotics in COVID-19 cases based on clinical assessments, focusing on the presence of bacterial infections rather than empirical treatment. Further research is necessary to more accurately identify patients with bacterial co-infections who would benefit from antibiotic treatment.

Keywords

Antibiotic usage
Bacterial co-infections
Mortality
COVID-19
SARS-CoV-2
Subject terms

Medical research
Infectious diseases
SARS-CoV-2
Antimicrobials
Antibiotics
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The COVID-19 pandemic has raised numerous challenges in managing hospitalized patients1. Given the paucity of specific antiviral therapy for COVID-19, supportive care has been a cornerstone of clinical management, with supplemental oxygen and mechanical ventilation being critical interventions for severe cases2,3. Even though COVID-19 is a viral disease, the empirical use of antibacterial agents is very common4,5. Bacterial co-infections are known to complicate viral respiratory illnesses, contribute to increased morbidity and mortality, and require prompt antibacterial therapy6,7. While bacterial co-infection rates in severe influenza can reach 20–30%, the prevalence and characteristics of such infections in COVID-19 patients are less well characterized7–9. Differentiating between COVID-19 and bacterial infections can be challenging due to overlapping symptoms and imaging findings, especially with limited resources10,11.

Current guidelines for community-acquired pneumonia recommend initial empirical antibiotic treatment due to the frequent coexistence of bacterial infections despite the lack of definitive diagnostic tests at the onset of pneumonia12,13. Preliminary studies suggest that antibiotics were prescribed in over 70% of COVID-19 cases, primarily based on suspicion of bacterial co-infection. However, emerging evidence suggests that actual rates of bacterial co-infection among hospitalized individuals with COVID-19 may be below 15%, with some studies reporting even lower figures13–15. The exact role of antibiotics in this respect is still unclear.

Furthermore, overuse of antibiotics in COVID-19 pneumonia can increase anti-microbial resistance and lead to complications such as Clostridium difficile infections and renal failure. Therefore, antibiotic decisions should be based on the risk of multi-drug-resistant bacteria and potential complications14,16,17.

The importance of rational antibiotic use cannot be overstated, as the irresponsible or incorrect use of these antimicrobials can lead to serious consequences. Overprescribing or inappropriate use of antibiotics can increase healthcare costs and contribute to the rise in the risk of drug toxicities and adverse drug interactions, thereby compromising patient safety18.

Understanding antibiotic prescribing patterns in COVID-19 may help improve the quality and safety of antibiotic use. This study aims to address the current knowledge gap by evaluating antibiotic use, identifying factors influencing antibiotic use, and assessing factors related to mortality in patients hospitalized with mild-to-severe COVID-19.

Materials and methods

Study design and setting

This retrospective cohort study enrolled patients who were hospitalized with a COVID-19 diagnosis at Bitlis Tatvan State and Kastamonu Training and Research Hospital between December 1, 2020, and June 1, 2022. A total of 445 patients met the inclusion criteria, which comprised those with SARS-CoV-2 detected by PCR (n = 431, 97%) or those with clinically compatible signs and symptoms (n = 14, 3%), bilateral pulmonary infiltrates, or high clinical suspicion lymphopenia. The bed occupancy rate was 93%. The Clinical Research Ethics Committee of KTO Karatay University approved this study (2022/019; 23.05.2022). Due to the retrospective nature of the study informed consent was waived by the KTO Karatay Ethics Committee and anonymous clinical data were utilized in the analysis. The research has been performed in accordance with the Declaration of Helsinki.

Participants

The preliminary and confirmed diagnoses of COVID-19 pneumonia, along with all treatment approaches, were determined following the guidelines established by the Ministry of Health Scientific Committee19. During the study period, all patients who were hospitalized with COVID-19 pneumonia were evaluated for eligibility. The inclusion criteria were as follows: the patient was 18 years or older, had positive nasal or nasopharyngeal RT-PCR test results or strong CT findings suggestive of COVID-19 pneumonia, and had not received antibiotics or had received antibiotic therapy within 24 h of admission. Eligible patients were included in the study if they were hospitalized. The study excluded subjects aged < 18 years or > 89 years, pregnant or lactating women, active malignancy, immunosuppressed subjects, and patients receiving additional antibiotic therapy for at least 24 h after hospital admission.

Data collection

A standard data collection form was used to collect demographic, clinical, laboratory, and radiological data from the electronic medical records (Sisohbys, Hospital Information Management System, Turkey). Only one result such as on antibiotic usage and biochemical parameters per patient was included in the study.

The presence of hypertension, history of smoking, chronic obstructive pulmonary disease (COPD), chronic cardiac conditions, diabetes mellitus, oral corticosteroid therapy during hospitalization, tumor presence, and immunosuppression was recorded.

During their hospitalization, from admission to discharge or death, patients' clinical symptoms and laboratory results were typically monitored as follows: Laboratory tests included routine blood tests such as complete blood count and serum biochemistry (including lactate dehydrogenase [LDH], creatinine, C-reactive protein [CRP], procalcitonin, ferritin, and D-dimer). CT scans were performed on all hospitalized patients. The criteria for determining disease severity on admission were based on the COVID-19 diagnosis and treatment protocols issued by the Turkish Ministry of Health19. The severity of infection was classified according to the NIH COVID-19 Treatment Guidelines at the time of hospital admission20. In addition, patient comorbidities and the Charlson Comorbidity Index (CCI), which estimates the risk of mortality, were documented21–23.

Antibiotic usage and other drugs

All medications taken during their hospital stay and COVID-19 vaccine information were also recorded. Medications prescribed for COVID-19 included favipiravir, lopinavir/ritonavir, corticosteroids, hydroxychloroquine, monoclonal antibodies (tocilizumab, anakinra), Intravenous immunoglobulin therapy (IVIG), COPD medications, antihypertensives, antidiabetics, antiarrhythmics, and antidepressant/antipsychotic drugs. The use of antibiotics in all patients who met the inclusion criteria was compared between survivors and non-survivors according to the severity of COVID-19. Classes of antibiotics prescribed (β-lactams, second- and third-generation cephalosporins, fluoroquinolones, glycopeptides, linezolid, colistin), time of antibiotic initiation (on admission or empiric vs post-admission), duration of treatment, antibiotic administration, the prevalence of bacterial co-infections (blood, respiratory and urinary tract) and antibiotic use rates were recorded. At the beginning of the first wave, studies reporting the efficacy of azithromycin in combination with hydroxychloroquine as a potential treatment for COVID-19 led to its widespread use, and azithromycin was prescribed both for this purpose and its antibacterial properties.

To determine the rate of bacterial co-infections among these patients, all positive microbiology results and suspected or culture-confirmed bacterial co-infections documented by the physician in clinical records after COVID-19 diagnosis were collected.

Statistical analysis

All statistical analyses were conducted using the IBM SPSS software, version 23 (IBM Corp., Armonk, N.Y., USA). Categorical variables are presented as frequencies (n) and percentages (%), while continuous variables are displayed as medians with interquartile ranges or means ± standard deviations (SD). Categorical variables were analyzed using the chi-square test or Fisher's exact test. The Kolmogorov–Smirnov test was used to confirm the normality assumption for continuous variables. For the comparison of independent continuous variables between survivors and non-survivors, the student's t-test or the Mann–Whitney U-test was utilized, depending on whether or not the statistical hypotheses were met. Repeated measures analysis of variance was conducted to compare differences between and within groups for time-dependent variables. A univariate and multivariate logistic regression model was employed to evaluate the association between antibacterial therapy and clinical mortality. For survival analysis, the multivariable Cox model was used to analyze the variables that were significant in comparing survival and non-survival variables. Odds ratios (ORs), Hazard ratios (HR), and 95% confidence intervals (CIs) were calculated and reported. The level of statistical significance for all tests was set at < 0.05.

Results

Patients and clinical characteristics with antibiotic usage

A total of 445 patients hospitalized with COVID-19 disease were included in the study. The mean age of the patients was 57 ± 18 years (range, 18–89 years). The mean age of patients receiving antibiotics was 60 ± 16 years, which was higher than that of those not receiving antibiotics, at 45 ± 18 years (p < 0.001). Of the patients, 274 (62%) were male and 171 (38%) were female. Nasal or nasopharyngeal RT-PCR tests for SARS-CoV-2 were confirmed positive in 431 (97%) of patients. The remaining 14 patients had bilateral lung infiltrates on their CT scans and a high clinical suspicion for COVID-19. The demographic and clinical profiles of the patients are detailed in Table 1.Table 1 Patient demographics and clinical characteristics between with antibiotic treatment (n = 354) and without antibiotic treatment (n = 91).

Characteristics	Total
(n = 445)	with antibiotic
(n = 354)	without antibiotic
(n = 91)	p-value	
Age mean (SD), years	56.6 ± 17.6	59.7 ± 16.4	44.7 ± 17.5	 < 0.001	
Sex	
 Women	171 (38.4%)	127 (35.9%)	44 (48.4%)	0.029	
 Man	274 (61.6%)	227 (64.1%)	47 (51.6%)		
Symptoms	
 Fever	138 (34.7%)	123 (36.9%)	15 (23.1%)	0.033	
 Dyspnoea	77 (17.3%)	70 (19.8%)	7 (7.7%)	0.007	
 Cough	254 (57.1%)	227 (64.1%)	27 (29.7%)	 < 0.001	
 Sore throat	287 (64.5%)	258 (72.9%)	29 (31.9%)	 < 0.001	
 Myalgia	119 (26.8%)	109 (30.8%)	10 (11.1%)	 < 0.001	
 Arthralgia	82 (18.4%)	70 (19.8%)	12 (13.2%)	0.173	
 Fatigue	242 (54.4%)	222 (62.7%)	20 (22.0%)	 < 0.001	
 Headache	110 (24.7%)	99 (28.0%)	11 (12.1%)	0.002	
 Diarrhea	12 (2.7%)	8 (2.3%)	4 (4.4%)	0.272	
 Nausea	74 (16.6%)	65 (18.4%)	9 (9.9%)	0.058	
 Chest pain	29 (6.5%)	25 (7.1%)	4 (4.4%)	0.478	
 Flutter	27 (6.1%)	27 (7.6%)	0 (0%)	0.002	
Smoking	
 Non-smoker	181 (65.3%)	129 (63.2%)	52 (71.2%)	0.352	
 Smoker	80 (28.9%)	61 (29.9%)	19 (26.0%)		
 Ex-smoker	16 (5.8%)	14 (6.9%)	2 (2.7%)		
Comorbid conditions	279 (62.7%)	244 (68.9%)	35 (38.5%)	 < 0.001	
 Hypertension	170 (38.2%)	148 (41.8%)	22 (24.2%)	0.002	
 Diabetes	74 (16.6%)	65 (18.4%)	9 (9.9%)	0.058	
 Coronary artery disease	88 (19.8%)	80 (22.6%)	8 (8.8%)	0.003	
 COPD	69 (15.5%)	62 (17.5%)	7 (7.7%)	0.021	
Related medications	
 Antihypertensives	175 (39.3)	152 (42.9)	23 (25.3)	0.002	
 Antidiabetic	66 (14.8%)	58 (16.4%)	8 (8.8%)	0.071	
 Immunosuppressive	10 (2.5%)	10 (2.8%)	0 (0%)	0.225	
 Inhaled corticosteroids β2 adrenergic agonists	57 (12.8%)	51 (14.4%)	6 (6.6%)	0.053	
Results were presented as mean ± standard deviation (SD) or count (n) and percentages (%). According to distribution Student t-test or Mann–Whitney U test was performed. p < 0.05, results were statistically significant. Chi-square test (or Fisher’s exact) was applied for categorical variables. COPD: Chronic obstructive pulmonary disease.

Significant values are in bold.

Patients were categorized into two groups based on whether or not they received antibiotic therapy. Antibiotics were administered in 354 cases (80%), while antibiotics were not used in 91 cases (20%).

Of all the patients, the most common symptom was sore throat (65%), followed by cough (57%) and fatigue (54%). In addition to these symptoms, myalgia, headache, arthralgia, nausea, and flutter were higher in antibiotic-treated patients (p < 0.05). Comorbidities were present in 279 (63%) patients. Compared to the without antibiotics group, comorbidities and the associated medications were higher in the antibiotic-treated group (p < 0.05, Table 1).

Clinical evaluation, medications, and laboratory results with antibiotic usage

During the follow-up period, 93 patients (21%) were admitted to the intensive care unit. Of these, 47 patients (11%) required invasive mechanical ventilation and 46 patients (10%) required non-invasive mechanical ventilation. Although the necessity for ICU admission varied among groups, the duration of ICU stays showed no differences. The mean hospital stay was 14 ± 10 days. The duration of hospital stays in the group receiving antibiotics was longer than the group not receiving antibiotics (p < 0.001).

Clinical evaluation scores for patients receiving and not receiving antibiotics were evaluated. The CCI was 3 (IQR, 1–5) in the antibiotic group and 1 (IQR, 0–3) in the non-antibiotic group (p < 0.001). Oxygen saturation (SO2) levels of the patients were evaluated during their hospital stay, on the day of admission for antibiotic treatment, and at the time of discharge. The groups receiving antibiotics had lower SO2 values upon admission (p < 0.001).

During the follow-up period, low- and high-dose corticosteroids were more commonly used in those receiving antibiotics, while hydroxychloroquine was more commonly used in those not receiving antibiotics. Furthermore, lopinavir/ritonavir (4%), tocilizumab/anakinra (3%), and IVIG (3%) were used only by the antibiotic group.

CT findings of 428 patients were evaluated during hospitalization. Pulmonary infiltration was detected in 192 (45%) of 428 patients; 151 patients received antibiotic treatment. Regarding in-hospital mortality, 55 out of 56 patients were in the antibiotic group, and one was in the non-antibiotic group (p < 0.001; Table 2).Table 2 The comparison of clinical evaluation and medications between with antibiotic treatment (n = 354) and without antibiotic treatment (n = 91).

Parameters	Total (n = 445)	with antibiotic (n = 354)	without antibiotic (n = 91)	p-value	
ICU admission	
 No	352 (79.1%)	265 (74.9%)	87 (95.6%)	 < 0.001	
 Yes	93 (20.9%)	89 (25.1%)	4 (4.4%)	
Intubation requirement	
 No-intubation	46 (10.3%)	43(12.1%)	3 (3.3%)		
 Intubation	47(10.6%)	46(13.0%)	1 (1.1%)		
 ICU duration median (IQR) (days)	10 (5–17)	10 (5–17)	3 ( 1–11)	0.163	
 Length of hospital stay median (IQR) (days)	11.5 (7–17)	12 (8–20)	7.5 (5–10)	 < 0.001	
Clinical evaluation scores	
 CCI median ( IQR)	2(1–4)	3 (1–5)	1 (0–2.5)	 < 0.001	
 SO2 (admission) median (IQR)	88 (81–92)	87 (80–91)	92 (88–96)	 < 0.001	
COVID-19 medications	
 Low-dose systemic corticosteroids	290 (65.2%)	246 (69.5%)	44 (48.4%)	 < 0.001	
 High-dose systemic corticosteroids	164 (36.9%)	148 (41.8%)	16 (17.6%)	 < 0.001	
 Hydroxychloroquine	123 (26.6%)	86 (24.3%)	37 (40.7%)	0.002	
 Pulmonary infiltration in the CT scan	192 (43.0%)	151 (44.8%)	41 (45.1%)	0.966	
 Lopinavir/Ritonavir	17 (3.8%)	17 (4.8%)	0 (0%)	0.030	
 Monoclonal antibodies (Tocilizumab/Anakinra)	13 (2.9%)	13 (3.7%)	0 (0%)	0.064	
 IVIG	13 (2.9%)	13 (3.7%)	0 (0%)	0.080	
 In-hospital mortality	56 (12.6%)	55 (15.5%)	1 (1.1%)	 < 0.001	
Results were presented as median (IQR) or count (n) and percentages (%). According to distribution Student t-test or Mann–Whitney U test was performed. Chi-square test (or Fisher’s exact) was applied for categorical variables. p < 0.05, results were statistically significant. ICU: Intensive Care Unit, CCl: Charlson Comorbidity Index, IQR: Interquartile Range, SO2: Oxygen Saturation, IVIG: Intravenous Immunoglobulin, CT: Computed Tomography.

Significant values are in bold.

Cultures were taken from 298 patients and 61 samples from 38 patients were positive (%13). 59 of the 61 positive cultures were seen in patients receiving antibiotics. The positive cultures were found in 26 blood, 15 sputum, and 20 urine samples. These cultures were accepted as microbiologically confirmed bacterial co-infection.

Table 3 presents the laboratory parameters with antibiotic usage. When laboratory parameters were compared between the antibiotic and without antibiotic groups, neutrophil, CRP (C-reactive protein), and ferritin levels were higher in the antibiotic group (Table 3).Table 3 The comparison of laboratory parameters between with antibiotic treatment (n = 354) and without antibiotic treatment (n = 91) at admission.

Laboratory Parameters	With antibiotic (n = 354)	Without antibiotic (n = 91)	p-value	
WBC (× 109/L, nr: 4 –10)	6400 (4680–9790)	5085 (3950–6300)	 < 0.001	
Neutrophil (× 109/L, nr: 1.3–7.4)	5215 (3625–8320)	3655 (2610–5180)	0.001	
Lymphocytes (× 109/L, nr: 0.9–5.3)	930 (670–1290)	1150 (780–1650)	0.014	
Platelets (1000 u/L), nr: 150–450)	188 (145–236)	190 (166–219)	0.596	
C-reactive protein (mg/L, nr: 0–5)	93 (47–157.2)	36.5 (5.7–74)	 < 0.001	
Ferritin (μmol/L, nr: 30–220)	225 (114.5–515.5)	166 (59–268)	0.001	
LDH (U/L, nr: 0–248)	356 (281–470)	311 (282–361)	0.099	
AST (U/L, nr: 0–35)	36 (26–50)	31.5 (23–39 )	0.988	
ALT (U/L, nr: 0–45)	27 (16–41)	25.5 (19–38)	0.036	
Creatinine (mg/dL, nr: 0.8–1.5)	1 (0.8–1.2)	0.9 (0.8–1.1)	0.242	
Results were presented as mean ± standard deviation (SD) or median (IQR). Independent sample T-test was used for these comparisons. p < 0.05, results were statistically significant. WBC: White blood cell counts, LDH: Lactate dehydrogenase, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, Nr: normal range, IQR: Interquartile Range.

Significant values are in bold.

Clinical characteristics and antibiotic usage of survivors and non-survivors

Table 4 present the survivors and non-survivors clinical characteristics and antibiotic usage. The survival rate among all patients was 87%. Non-survivors (69 ± 12) were older than survivors (55 ± 18; p < 0.001). In addition, the proportion of non-survivors was substantially higher in males (%80).Table 4 The comparison of patient demographics and clinical characteristics between the survivors (n = 389) and the non-survivors (n = 56).

Parameters	Total
(%100)	Non-Survivors
(12.6%)	Survivors (87.4%)	p-value	
Age mean (SD), years	56.6 ± 17.6	68.9 ± 12.4	54.9 ± 17.6	 < 0.001	
 Sex		56 (12.6)	389 (87.4)	0.002	
 Female	171 (38.4)	11 (19.6)	160 (41.1)		
 Male	274 (61.6)	45 (80.4)	229 (58.9)		
Severity of COVID Disease (NIH)				 < 0.001	
 Mild	186 (41.8)	0(0)	186 (47.8)		
 Moderate	85 (19.1)	13 (23.2)	72 (18.5)		
 Severe	174 (39.1)	43 (76.8)	131 (33.7)		
 Length of hospital stay mean (SD) (days)	14.2 ± 9.8	21.1 ± 13.4	12.8 ± 8.3	 < 0.001	
 ICU admission	93 (20.9)	56 (62.1)	37 (37.9)	 < 0.001	
 Intensive care duration mean (SD) (days)	13.3 ± 12.5	17.1 ± 12.8	8 ± 10	0.001	
Antibiotics	
 Duration of Antibiotic Therapy	11.5 ± 6.8	18.1 ± 8.8	10 ± 5.1	 < 0.001	
 Any antibiotic	354 (77.8)	55 (98.2)	299 (76.9)	 < 0.001	
 Beta-lactams	77 (17.3)	8 (14.29)	69 (17.74)	0.523	
 Fluoroquinolones	108 (24.27)	4 (7.14)	104 (26.74)	0.001	
 Beta-lactams + Fluoroquinolones	70 (15.73)	12 (21.43)	58 (14.91)	0.210	
 Beta-Lactams + Fluoroquinolones + Glycopeptide or linezolid	17 (3.82)	13 (23.21)	4 (1.03)	 < 0.001	
 Beta-Lactams + Fluoroquinolones + Glycopeptide or linezolid + Colistin	16 (3.60)	16 (28.57)	0 (0)	 < 0.001	
 Others	8 (1.80)	2 (3.57)	6 (1.54)	0.266	
 Macrolides (Azithromycin)	87 (19.6)	3 (5.4)	84 (21.6)		
Results were presented as mean ± standard deviation (SD; median Q1-Q3) or count (n) and percentages (%). According to distribution Student t-test or Mann–Whitney U test was performed. Chi-square test (or Fisher’s exact) was applied for categorical variables. p < 0.05, results were statistically significant. ICU: Intensive Care Unit.

Significant values are in bold.

As defined by NIH guidelines20, 445 COVID-19 patients were categorized into three groups according to the severity of their disease: mild (42% (n = 186), moderate (19% (n = 85), and severe (39% (n = 174). All mild COVID-19 patients were included in the survivors.

The mean length of hospital stay was 14 ± 10 days. The length of hospital stay was longer in non-survivors (21 ± 13) than in survivors (13 ± 8). In terms of ICU admission was higher among non-survivors (62%). The mean length of ICU stay was also higher among non-survivors (18 ± 13) than survivors (8 ± 10; p = 0.001).

During follow-up, 354 patients were treated with antibiotics for 12 ± 7 days. The duration of antibiotic treatment was 18 ± 9 days in the non-survivors, while it was 10 ± 5 days in the survivors (p < 0.001).

While 299 (77%) of the 389 survivors were treated with antibiotics, 55 of the 56 non-survivors were treated with antibiotics. The most frequently used antibiotics were the fluoroquinolones, followed by the beta-lactam antibiotics. In addition, a combination of glycopeptide, linezolid, and colistin was also given. Within the fluoroquinolones, moxifloxacin (n = 117), levofloxacin (n = 88), and ciprofloxacin (n = 6) were used. Of the remaining patients, 17 used glycopeptides or linezolid, and 16 used colistin. The distribution of antibiotics prescribed is given in Table 4.

Univariable and multivariable logistic regression analysis influencing antibiotic use in patients with COVID-19

Table 5 presents the univariable and multivariable logistic regression analysis influencing antibiotic use in patients with COVID-19. Logistic regression analysis was used to determine factors associated with antibiotic use. Variables significant (p < 0.05) or borderline significant in other analyses were included in univariate logistic regression analysis (p < 0.10).Table 5 Presents the results of the univariate and multivariate logistic regression models, analyzing the factors influencing antibiotic use in patients with COVID-19.

Parameters	Univariate logistic regressions
OR (95% CI)	p-value	Multivariate logistic regressions
OR (95% CI)	p-value	
Age	1.053 (1.037–1.069)	 < 0.001	0.988 (0.946–1.032)	0.595	
Gender (male)	1.673 (1.051–2.664)	0.030	0.793 (0.349–1.799)	0.578	
CCI	1.434 (1.198–1.716)	 < 0.001	1.565 (1.052–2.327)	0.027	
Steroid used	2.499 (1.562–3.988)	 < 0.001	1.168 (0.274–4.976)	0.834	
ICU admission	7.305 (2.606–20.474)	 < 0.001	8.797 (1.086–71.240)	0.042	
Pneumonic infiltration	0.990 (0.622–1.577)	0.966			
Oxygen saturation (SO2/room air )	0.889 (0.852–0.927)	 < 0.001	0.988 (0.938–1.041)	0.650	
C-reactive protein (> 50)	4.533 (2.456–8.366)	 < 0.001	2.273 (1.008–5.125)	0.048	
Neutrophil (> 7.1*103)	2.284 (0.911–5.723)	0.078			
OR: Odds Ratio, CI: Confidence Interval, CCI: Charlson Comorbidity Index, SO2: Oxygen Saturation. p < 0.05, results were statistically significant. *Wald test.

Significant values are in bold.

Univariate regression analysis was performed on eight variables: age, sex, pneumonic infiltration, SO2 on admission, ICU admission, CCI, corticosteroid use, CRP, and neutrophil count on admission. The multivariate regression analysis included the variables found to be statistically significant in the univariate regression analysis and we found that CCI (OR 1.6 [95% CI 1.1–2.3]), CRP levels (OR 2.3 [95% CI 1–5.1]), and ICU admissions (OR 8.8 [95% CI 1.1–71.3]) influence antibiotic prescriptions (Table 5).

We also examined the Cox regression analysis to assess the factors related to in-hospital mortality in mild to severe COVID-19 disease. However, we did not find an association between antibiotic use and mortality (HR 2.7 [95% CI 0.4–20] (Table 6), but there was just one death in the non-antibiotics group.Table 6 Multivariate Cox regression model for mortality in patients with COVID-19.

Parameters	Univariate cox regressions HR (95% CI)	p-value	Multivariate cox regressions HR (95% CI)	p-value	
Age	1.032 (1.009–1.055)	0.006	1.035 (0.998–1.074)	0.067	
Gender (male)	1.582 (0.762–2.272)	0.216	1.489 (0.712–3.113)	0.290	
Antibiotic treatment	3.491 (0.479–25.450)	0.217	2.703 (0.365–20.045)	0.331	
Severity of COVID-19 Disease	1.154 (0.678–1.964)	0.598	1.153 (0.649–2.048)	0.627	
CCI	1.134 (1.005–1.279)	0.042	0.971 (0.782–1.206)	0.792	
HR: Hazard Ratio, CI: Confidence Interval, CCI: Charlson Comorbidity Index. p < 0.05, results were statistically significant.

*Among the study participants, 299 (77%) of the 389 survivors received antibiotic treatment. In terms of in-hospital mortality, 55 of the 56 non-survivors (98%) were in the antibiotic group, and one was in the non-antibiotic group.

Significant values are in bold.

Discussion

A key challenge during the COVID-19 pandemic has been the lack of substantial evidence of reliable treatment options24,25. Due to the virus's ability to change rapidly and the newness of the disease, the uncertainty of proven and effective treatments has led to challenges in clinical management26. Although COVID-19 is a viral disease, antibiotics may have to be prescribed in several situations, such as a concurrent clinical suspicion of bacterial pneumonia, patients with multiple comorbidities, or elevated markers of inflammation27. These factors raise concerns about bacterial co-infections and may influence decisions to prescribe antibiotics as a precautionary measure to prevent potential bacterial complications.

This retrospective cohort study demonstrated a high rate of antibiotic prescriptions in hospitalized COVID-19 patients from two health centers in Turkey. Approximately 80% of the patients included in the study received antibiotics during their hospitalization. Despite the high rate of antibiotic prescriptions, microbiologically confirmed bacterial co-infections were relatively low in our study, with only 14% of patients being affected. The bacterial co-infection rates vary from one country to another and even in different communities within the same country, ranging from 3 to 53% in COVID-19 patients25,28–34.

A study conducted in the United States showed a high antibiotic prescribing rate, reaching 83% of patients who received at least one course of antibiotics despite a low rate of microbiologically confirmed infection (12%)30. In a retrospective study of 1269 COVID-19 patients in 2020–2022 in two Italian hospitals, 84% of patients (n = 1062) received antibiotic treatment, with only 15% having an obvious source of bacterial infection31. A multicentre point-prevalence study conducted in Turkey with a large participant population showed that the antibiotic prescription rate was 75%. However, the rate of clinically or microbiologically confirmed bacterial infections was 29%, and culture positivity was 7%25. In our study, the relationship between antibiotic prescription rate and microbiologically confirmed bacterial co-infection was consistent with previous studies.

Two systematic reviews and meta-analyses by Langford et al. reported the prevalence of antibiotic prescription to be 72% (95% CI 56 to 88%) and 75% (95% CI 68–80%), and the prevalence of bacterial co-infection to be 7% (95% CI 4–10%) and 9% (95% CI 5–15%), respectively32,33. The high antibiotic prescribing rate compared to the low bacterial co-infection rate in our study and other studies may be related to empirical antibiotic use and the severe clinical conditions of the patients.

In early studies, clinicians followed the initiation of treatment for COVID-19 patients based on local guidelines for community-acquired pneumonia12. In addition, some medical centers have recommended empiric antibiotics for the majority of COVID-19 patients based on institutional guidelines30. The most commonly used antibiotics in the treatment of COVID-19 patients are fluoroquinolones, macrolides, and beta-lactams25,30,33. In our study, respiratory fluoroquinolones such as levofloxacin, moxifloxacin, and ciprofloxacin were the most prescribed antibiotics, followed by beta-lactams, especially second/third-generation cephalosporins. These results suggest that healthcare providers prefer these antibiotics to treat respiratory tract infections, especially in COVID-19 patients. In addition, beta-lactams, fluoroquinolones, and their combinations were more commonly used in survivors. In contrast, high-end antibiotics such as glycopeptide/linezolid and colistin were more commonly used in non-survivors (p < 0.001). This highlights the importance of disease severity and specific medical interventions to guide antibiotic prescribing decisions in critically ill patients.

Understanding the predictive factors for the need for antibiotic treatment not only ensures proper management of antibiotic therapy but also improves the patient's overall prognosis and enhances the management of antimicrobial resistance (AMR)33.

The patient's comorbidities, clinical symptoms, and laboratory findings were evaluated to determine whether or not they had received antibiotic treatment. The lack of precise data on the relationship between comorbidity and antibiotic use in COVID-19 may have led to a perception that antibiotics were prescribed at a higher rate in patients without comorbidities. Al-Hadidi et al. reported no difference in antibiotic use between patients with and without comorbidities34. In contrast to this study, we observed that comorbidities and the use of medications associated with comorbidities were higher in the group receiving antibiotics. Calderón-Parra et al. concluded that fewer comorbidities, dry cough, and flu-like symptoms may be associated with inappropriate antibiotic use14. In our study, flu-like symptoms such as sore throat, cough, fatigue, myalgia, arthralgia, headache, and nausea were more common in patients treated with antibiotics.

Laboratory abnormalities have contributed to the use of antibiotics in COVID-19 patients. A recent meta-analysis indicated that procalcitonin (PCT) has limited predictive value for detecting co-infection in patients with COVID-19. However, lower PCT levels appear to be associated with a reduced probability of co-infection35.

Although studies have shown that elevated CRP levels are associated with an increased frequency of antibiotic prescription, CRP is not a reliable indicator of antibiotic prescription during the COVID-19 pandemic. This may be due to the respiratory distress leading to elevated CRP levels observed in the initial presentation of patients with COVID-1925,36–38. In our study, we observed that elevated CRP levels in patients who received antibiotics contributed to increased antibiotic use. However, PCT (procalcitonin) values could not be assessed for all patients due to limited laboratory resources.

In our study, we used univariate logistic regression analysis to determine factors associated with antibiotic use. We identified eight independent factors that were associated with an increased use of antibiotics. These factors are as follows: age, gender, Charson comorbidity index, requirement for supplemental oxygen, steroid usage, presence of moderate/diffuse lung involvement, neutrophil count, and C-reactive protein levels. These factors significantly influenced the higher antibiotic utilization among the individuals included in the study (Table 5).

A study in Turkey identified several risk factors associated with antibiotic use in COVID-19 patients, including age, hospitalization in ICU, need for supplemental oxygen, moderate or diffuse lung involvement, and a lymphocyte count < 800. It was also reported that moderate or extensive lung involvement and CRP levels above the upper limit of normal (ULT) were associated with antibiotic use25. In a meta-analysis study conducted on 30,212 patients, it was observed that antibiotic prescribing prevalence was more common in older age groups and in patients with higher severity of illness33.

In our study, the in-hospital mortality rate was 12.6%, which is in line with the results of other studies in the literature31. Mortality was observed in 14.1% of the patients treated with antibiotics. The group of patients receiving antibiotics consisted of clinically more severe cases with high pulmonary infiltration, low SO2 saturation and high comorbidities. Thus, the severity of illness was also a cause for administering antibiotics, creating a selection bias between the two groups. We also wanted to examine the effect of antibiotics on mortality; however, due to the presence of selection bias, this analysis could not be effectively evaluated. Although our study did not find an association between antibiotic use and increased mortality, we observed that patients treated with antibiotics had higher rates of comorbidities and severe forms of COVID-19.

Some limitations should be recognized for this study. The retrospective nature of this study, the small number of patients, and the fact that it was a two-center study conducted predominantly in the Turkish population may limit the generalizability of the results. In addition to the fact that similar microbiologic tests were performed in patients and only the results of positive tests were reported, there is also a lack of data on isolated bacteria and their antibiotic susceptibility. Furthermore, bacterial co-infections may have been missed due to antibiotic treatment before hospitalization, and microbiology sampling may have influenced microbiology test results. The presence of an unknown false-negative rate for cultivation. Another limitation is that it was not possible to measure PCT levels in all patients due to laboratory problems, and the duration of MV support is unknown. Although our study has several limitations, its strength is that it covers both the quarantine period and the period when no strict pandemic measures were taken (December 2020 to June 2022).

Conclusion

In summary, our study reveals a concerning trend of considerable antibiotic use in COVID-19 patients, even in the absence of clinical or laboratory diagnosis. This practice may have serious consequences due to the low rate of bacterial co-infection and the potential risks associated with antibiotic use, such as the development of antimicrobial resistance and drug-induced toxicity. Therefore, it is crucial to limit the empirical use of antibiotics in COVID-19 patients and to consider antibiotic treatment only when there is clear microbiologic evidence or strong clinical suspicion of bacterial infection. These precautions minimize the potential harm of unnecessary antimicrobial use while preserving the efficacy of these important drugs for future medical needs. Further research is necessary to more accurately identify patients with bacterial co-infections who would benefit from antibiotic treatment.

Acknowledgements

None.

Author contributions

H.N.K.: Conceptualization; Methodology; Formal analysis; Investigation; Data curation; Writing-original draft; Supervision; MA: Formal Analysis; Data curation; Writing-original draft; Writing-review & editing; SÖ: Methodology; Investigation; YO: Methodology; Investigation; ES: Data curation; Writing-original draft; Writing-review& editing; EKD: Methodology; Investigation; YKA: Formal Analysis; Data curation; MMS: Writing-original draft; Writing-review & editing; Supervision. All authors reviewed the manuscript.

Data availability

The datasets generated during the current study are not publicly available due to the hospital’s personal data protection policy but are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Mohammadinia L Hospital response challenges and strategies during COVID-19 pandemic: A qualitative study Front Public Health. 2023 11 1167411 10.3389/fpubh.2023.1167411 37457272
Mohammadinia, L. et al. Hospital response challenges and strategies during COVID-19 pandemic: A qualitative study. Front Public Health. 11, 1167411. 10.3389/fpubh.2023.1167411 (2023).37457272 10.3389/fpubh.2023.1167411
2. Alfano, G., et al. Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19. Infez Med. 30(1), 11–21. 10.53854/liim-3001-2 (2022).
3. Sanders JM Monogue ML Jodlowski TZ Cutrell JB Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review JAMA. 2020 323 18 1824 1836 10.1001/jama.2020.6019 32282022
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA. 323(18), 1824–1836. 10.1001/jama.2020.6019 (2020).32282022 10.1001/jama.2020.6019
4. Huttner BD Catho G Pano-Pardo JR Pulcini C Schouten J COVID-19: don't neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020 26 7 808 810 10.1016/j.cmi.2020.04.024 32360446
Huttner, B. D., Catho, G., Pano-Pardo, J. R., Pulcini, C. & Schouten, J. COVID-19: don’t neglect antimicrobial stewardship principles!. Clin Microbiol Infect. 26(7), 808–810. 10.1016/j.cmi.2020.04.024 (2020).32360446 10.1016/j.cmi.2020.04.024
5. Paula HSC An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic Braz J Med Biol Res. 2021 55 e11631 10.1590/1414-431X2021e11631 34909910
Paula, H. S. C. et al. An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic. Braz J Med Biol Res. 55, e11631. 10.1590/1414-431X2021e11631 (2021).34909910 10.1590/1414-431X2021e11631
6. Rothe K Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: A retrospective cohort study in light of antibiotic stewardship Eur J Clin Microbiol Infect Dis. 2021 40 4 859 869 10.1007/s10096-020-04063-8 33140176
Rothe, K. et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: A retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis. 40(4), 859–869. 10.1007/s10096-020-04063-8 (2021).33140176 10.1007/s10096-020-04063-8
7. Alshaikh FS Godman B Sindi ON Seaton RA Kurdi A Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: A systematic review and meta-analysis PLoS One. 2022 17 8 e0272375 10.1371/journal.pone.0272375 35913964
Alshaikh, F. S., Godman, B., Sindi, O. N., Seaton, R. A. & Kurdi, A. Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: A systematic review and meta-analysis. PLoS One. 17(8), e0272375. 10.1371/journal.pone.0272375 (2022).35913964 10.1371/journal.pone.0272375
8. Rice TW Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States Crit Care Med. 2012 40 5 1487 1498 10.1097/CCM.0b013e3182416f23 22511131
Rice, T. W. et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med. 40(5), 1487–1498. 10.1097/CCM.0b013e3182416f23 (2012).22511131 10.1097/CCM.0b013e3182416f23
9. Westblade LF Simon MS Satlin MJ Bacterial coinfections in coronavirus disease 2019 Trends Microbiol. 2021 29 10 930 941 10.1016/j.tim.2021.03.018 33934980
Westblade, L. F., Simon, M. S. & Satlin, M. J. Bacterial coinfections in coronavirus disease 2019. Trends Microbiol. 29(10), 930–941. 10.1016/j.tim.2021.03.018 (2021).33934980 10.1016/j.tim.2021.03.018
10. Liu C Wen Y Wan W Lei J Jiang X Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19 Int Immunopharmacol. 2021 90 107157 10.1016/j.intimp.2020.107157 33187911
Liu, C., Wen, Y., Wan, W., Lei, J. & Jiang, X. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. Int Immunopharmacol. 90, 107157. 10.1016/j.intimp.2020.107157 (2021).33187911 10.1016/j.intimp.2020.107157
11. Feldman C Anderson R The role of co-infections and secondary infections in patients with COVID-19 Pneumonia (Nathan). 2021 13 1 5 10.1186/s41479-021-00083-w 33894790
Feldman, C. & Anderson, R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan). 13(1), 5. 10.1186/s41479-021-00083-w (2021).33894790 10.1186/s41479-021-00083-w
12. Sieswerda E Recommendations for antibacterial therapy in adults with COVID-19: An evidence based guideline Clin Microbiol Infect. 2021 27 1 61 66 10.1016/j.cmi.2020.09.041 33010444
Sieswerda, E. et al. Recommendations for antibacterial therapy in adults with COVID-19: An evidence based guideline. Clin Microbiol Infect. 27(1), 61–66. 10.1016/j.cmi.2020.09.041 (2021).33010444 10.1016/j.cmi.2020.09.041
13. Sturza F Guță ȘD Popescu GA Antibiotics used for COVID-19 in-patients from an infectious disease ward Antibiotics (Basel). 2023 12 1 150 10.3390/antibiotics12010150 36671351
Sturza, F., Guță, ȘD. & Popescu, G. A. Antibiotics used for COVID-19 in-patients from an infectious disease ward. Antibiotics (Basel). 12(1), 150. 10.3390/antibiotics12010150 (2023).36671351 10.3390/antibiotics12010150
14. Calderón-Parra J Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications: analysis of the registry SEMI-COVID PLoS One. 2021 16 5 e0251340 10.1371/journal.pone.0251340 33974637
Calderón-Parra, J. et al. Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications: analysis of the registry SEMI-COVID. PLoS One. 16(5), e0251340. 10.1371/journal.pone.0251340 (2021).33974637 10.1371/journal.pone.0251340
15. Cong W Antimicrobial use in COVID-19 patients in the first phase of the SARS-CoV-2 pandemic: A scoping review Antibiotics (Basel). 2021 10 6 745 10.3390/antibiotics10060745 34205440
Cong, W. et al. Antimicrobial use in COVID-19 patients in the first phase of the SARS-CoV-2 pandemic: A scoping review. Antibiotics (Basel). 10(6), 745. 10.3390/antibiotics10060745 (2021).34205440 10.3390/antibiotics10060745
16. Cheng LS Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: Experience from a single hospital cluster Ther Adv Infect Dis. 2020 7 2049936120978095 10.1177/2049936120978095 33335724
Cheng, L. S. et al. Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: Experience from a single hospital cluster. Ther Adv Infect Dis. 7, 2049936120978095. 10.1177/2049936120978095 (2020).33335724 10.1177/2049936120978095
17. Lai CC Chen SY Ko WC Hsueh PR Increased antimicrobial resistance during the COVID-19 pandemic Int J Antimicrob Agents. 2021 57 4 106324 10.1016/j.ijantimicag.2021.106324 33746045
Lai, C. C., Chen, S. Y., Ko, W. C. & Hsueh, P. R. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents. 57(4), 106324. 10.1016/j.ijantimicag.2021.106324 (2021).33746045 10.1016/j.ijantimicag.2021.106324
18. de With K Strategies to enhance rational use of antibiotics in hospital: A guideline by the German Society for Infectious Diseases Infection. 2016 44 3 395 439 10.1007/s15010-016-0885-z 27066980
de With, K. et al. Strategies to enhance rational use of antibiotics in hospital: A guideline by the German Society for Infectious Diseases. Infection. 44(3), 395–439. 10.1007/s15010-016-0885-z (2016).27066980 10.1007/s15010-016-0885-z
19. The Turkish Ministry of Health. General Directorate of Public Health. COVID-19 (SARS-CoV-2 infection) Guide, 2020. Available from: https://www.fip.org/files/content/priorityareas/coronavirus/moresources/Turkey_SARSCoV2InfectionGuide.pdf. Accessed on 19 Oct 2020.
20. National Institutes of Health (NIH). COVID-19 treatment guidelines: clinical spectrum of SARS CoV-2 infection. Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed on 29 Feb 2024.
21. WHO. World Health Organization Coronavirus disease (COVID-2019) R&D, 2020. Avaliable from: https://www.who.int/teams/blueprint/covid-19. Accessed 22 Dec 2020.
22. Charlson ME Pompei P Ales KL MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chronic Dis. 1987 40 5 373 383 10.1016/0021-9681(87)90171-8 3558716
Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 40(5), 373–383. 10.1016/0021-9681(87)90171-8 (1987).3558716 10.1016/0021-9681(87)90171-8
23. Tuty Kuswardhani RA Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis Diabetes Metab Syndr. 2020 14 6 2103 2109 10.1016/j.dsx.2020.10.022 33161221
Tuty Kuswardhani, R. A. et al. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Metab Syndr. 14(6), 2103–2109. 10.1016/j.dsx.2020.10.022 (2020).33161221 10.1016/j.dsx.2020.10.022
24. Robinson PC COVID-19 therapeutics: Challenges and directions for the future Proc Natl Acad Sci USA 2022 119 15 e2119893119 10.1073/pnas.2119893119 35385354
Robinson, P. C. et al. COVID-19 therapeutics: Challenges and directions for the future. Proc Natl Acad Sci USA 119(15), e2119893119. 10.1073/pnas.2119893119 (2022).35385354 10.1073/pnas.2119893119
25. Şencan İ Antibiotic use and influencing factors among hospitalized patients with COVID-19: A multicenter point-prevalence study from Turkey Balkan Med J. 2022 39 3 209 217 10.4274/balkanmedj.galenos.2022.2021-11-62 35611705
Şencan, İ et al. Antibiotic use and influencing factors among hospitalized patients with COVID-19: A multicenter point-prevalence study from Turkey. Balkan Med J. 39(3), 209–217. 10.4274/balkanmedj.galenos.2022.2021-11-62 (2022).35611705 10.4274/balkanmedj.galenos.2022.2021-11-62
26. Mahomedradja RF Prescribing errors in post - COVID-19 patients: Prevalence, severity, and risk factors in patients visiting a post-COVID-19 outpatient clinic BMC Emerg Med. 2022 22 1 35 10.1186/s12873-022-00588-7 35247982
Mahomedradja, R. F. et al. Prescribing errors in post - COVID-19 patients: Prevalence, severity, and risk factors in patients visiting a post-COVID-19 outpatient clinic. BMC Emerg Med. 22(1), 35. 10.1186/s12873-022-00588-7 (2022).35247982 10.1186/s12873-022-00588-7
27. Pinte L Antibiotic prescription and in-hospital mortality in COVID-19: A prospective multicentre cohort study J Pers Med. 2022 12 6 877 10.3390/jpm12060877 35743662
Pinte, L. et al. Antibiotic prescription and in-hospital mortality in COVID-19: A prospective multicentre cohort study. J Pers Med. 12(6), 877. 10.3390/jpm12060877 (2022).35743662 10.3390/jpm12060877
28. Wang L An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London J Antimicrob Chemother. 2021 76 3 796803 10.1093/jac/dkaa475
Wang, L. et al. An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. J Antimicrob Chemother. 76(3), 796803. 10.1093/jac/dkaa475 (2021).10.1093/jac/dkaa475
29. Jeong S Prevalence and clinical impact of coinfection in patients with coronavirus disease 2019 in Korea Viruses. 2022 14 2 446 10.3390/v14020446 35216039
Jeong, S. et al. Prevalence and clinical impact of coinfection in patients with coronavirus disease 2019 in Korea. Viruses. 14(2), 446. 10.3390/v14020446 (2022).35216039 10.3390/v14020446
30. Martin AJ Shulder S Dobrzynski D Quartuccio K Pillinger KE Antibiotic use and associated risk factors for antibiotic prescribing in COVID-19 hospitalized patients J Pharm Pract. 2023 36 2 256 263 10.1177/08971900211030248 34291681
Martin, A. J., Shulder, S., Dobrzynski, D., Quartuccio, K. & Pillinger, K. E. Antibiotic use and associated risk factors for antibiotic prescribing in COVID-19 hospitalized patients. J Pharm Pract. 36(2), 256–263. 10.1177/08971900211030248 (2023).34291681 10.1177/08971900211030248
31. Lee J Bacterial co-infection and empirical antibacterial therapy in patients with COVID-19 J Korean Med Sci. 2023 38 4 e37 10.3346/jkms.2023.38.e37 36718563
Lee, J. et al. Bacterial co-infection and empirical antibacterial therapy in patients with COVID-19. J Korean Med Sci. 38(4), e37. 10.3346/jkms.2023.38.e37 (2023).36718563 10.3346/jkms.2023.38.e37
32. Langford BJ Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis Clin Microbiol Infect. 2020 26 12 1622 1629 10.1016/j.cmi.2020.07.016 32711058
Langford, B. J. et al. Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clin Microbiol Infect. 26(12), 1622–1629. 10.1016/j.cmi.2020.07.016 (2020).32711058 10.1016/j.cmi.2020.07.016
33. Che Yusof R Norhayati MN Mohd Azman Y Bacterial coinfection and antibiotic resistance in hospitalized COVID-19 patients: A systematic review and meta-analysis PeerJ. 2023 11 e15265 10.7717/peerj.15265 37128208
Che Yusof, R., Norhayati, M. N. & Mohd Azman, Y. Bacterial coinfection and antibiotic resistance in hospitalized COVID-19 patients: A systematic review and meta-analysis. PeerJ. 11, e15265. 10.7717/peerj.15265 (2023).37128208 10.7717/peerj.15265
34. Al-Hadidi SH The spectrum of antibiotic prescribing during COVID-19 pandemic: A systematic literature review Microb Drug Resist. 2021 27 12 1705 1725 10.1089/mdr.2020.0619 34077290
Al-Hadidi, S. H. et al. The spectrum of antibiotic prescribing during COVID-19 pandemic: A systematic literature review. Microb Drug Resist. 27(12), 1705–1725. 10.1089/mdr.2020.0619 (2021).34077290 10.1089/mdr.2020.0619
35. Wei S Wang L Lin L Liu X Predictive values of procalcitonin for coinfections in patients with COVID-19: A systematic review and meta-analysis Virol J. 2023 20 1 92 10.1186/s12985-023-02042-x 37158904
Wei, S., Wang, L., Lin, L. & Liu, X. Predictive values of procalcitonin for coinfections in patients with COVID-19: A systematic review and meta-analysis. Virol J. 20(1), 92. 10.1186/s12985-023-02042-x (2023).37158904 10.1186/s12985-023-02042-x
36. Ponti G Maccaferri M Ruini C Tomasi A Ozben T Biomarkers associated with COVID-19 disease progression Crit Rev Clin Lab Sci. 2020 57 6 389 399 10.1080/10408363.2020.1770685 32503382
Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A. & Ozben, T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 57(6), 389–399. 10.1080/10408363.2020.1770685 (2020).32503382 10.1080/10408363.2020.1770685
37. Tjendra Y Predicting disease severity and outcome in COVID-19 patients: A review of multiple biomarkers Arch Pathol Lab Med. 2020 144 12 1465 1474 10.5858/arpa.2020-0471-SA 32818235
Tjendra, Y. et al. Predicting disease severity and outcome in COVID-19 patients: A review of multiple biomarkers. Arch Pathol Lab Med. 144(12), 1465–1474. 10.5858/arpa.2020-0471-SA (2020).32818235 10.5858/arpa.2020-0471-SA
38. Pink I C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19 Infection. 2021 49 5 935 943 10.1007/s15010-021-01615-8 34021897
Pink, I. et al. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection. 49(5), 935–943. 10.1007/s15010-021-01615-8 (2021).34021897 10.1007/s15010-021-01615-8
